

British Liver Trust Primary Care Pathway Survey - Survey Questions

Q1. Name and position of person answering the survey
Dr Manik Arora, Deputy Medical Director
Q2. Please enter the name of your ICB
NHS Nottingham and Nottinghamshire ICB
Q3. Do you have a named person within the ICB who is responsible for liver disease?
□ Yes
⊠ No
If yes, please move to Q3a
If no, please move to Q3b
Q3a If yes, please provide the name, title and email address of this person
Not applicable.
Q3b In the absence of a named contact for liver disease, please provide the name, title and email address of the person who should be contacted regarding liver health
Name: Dave Briggs
Title: Medical Director
Email address: General Enquiries - NHS Nottingham and Nottinghamshire ICB
Q4. Do you have a commissioned pathway for a) the interpretation of abnormal liver blood tests? b) responding to liver disease more generally? Please could you attach/hyperlink any pathway documents to your response.
☐ Yes, pathways for both
\square Yes, pathway for abnormal liver blood tests
☐ No pathways for either
Please see additional PDF document for more details.

If answer to any of these is yes, please move to Q5

If answer is no pathways for either, please move to Q8

Q5. Is/Are the pathway(s) rolled out across the entire ICB or CCG locality specific?
☐ Yes, across the entire ICB
Q6. Does it include an endorsed pathway for the management of abnormal liver blood tests that follows the BSG guidance?
⊠ Yes
□ No
□ Not applicable
Q7. Is liver fibrosis assessment part of your pathway?
⊠ Yes
□ No
□ Not applicable
If yes, please move to Q7a
If no, please move to Q8
Q7a. Please indicate how fibrosis is assessed (Please tick all that apply):
⊠ Fibroscan
□ ELF Test
□ NAFLD fibrosis score
□ iLFTs
□ Other:
Q8. Do you have an additional pathway that <u>proactively</u> case-finds individuals who may be at high-risk of liver disease?
⊠ Yes
□ No

If yes, please move to Q9

If no, please move to Q11

Q9. How does your pathway define individuals as high risk of liver disease? (Please tick all that apply)
□ Diabetes
⊠ Alcohol risk
□ Obesity □
☐ Obesity with other metabolic risk factors
☐ Risk factors for viral hepatitis
☐ Other:
Q10. How are these individuals identified? (Please tick all that apply)
$\hfill\square$ At annual chronic disease or year of care review
☐ During the NHS Health Check
☐ Opportunistically during consultations
☐ Using IT system prompts or pop-ups
☑ Other: High-risk patients are identified using primary/secondary care data collated in the GPRCC and shared with secondary care who invite them for a community Fibroscan. PCNs with high levels of socioeconomic deprivation are prioritised for the case finding PHM initiative.
Q11: Does your contract with Drug and Alcohol Recovery Service providers include providing a liver disease diagnostic test?
□ Yes
⊠ No
Q12: Does your contract with Weight Management Service providers include providing a liver disease diagnostic test?
□ Yes
⊠ No

Q13. Does the ICB monitor the breadth of adoption and efficacy of liver disease pathways in primary care in your area?
□ Yes
⊠ No
If yes, please move to Q14
If no, please move to Q15
Q14. Where are these statistics published?
Not applicable.
Q15. Are you aware of current statistics relating to liver disease in your area and do you monitor these?
□ Yes
⊠ No
Q16. Which Community Diagnostic Centre(s) serve your ICB?
The ICB has no CDCs at present.
Q17. Is/Are your local Community Diagnostic Centre(s) used for liver disease diagnostics?
□ Yes
⊠ No – see Q16.
Q18. Would you be willing to share your pathway information with other ICBs for best practice purposes? This question is not relevant to a request for a corporate record/information under the FOI Act.
□ Yes
□ No
☐ Not applicable
Q19. Would you like to meet with the British Liver Trust and/or a local clinician to find out how you can improve liver disease in your area? (optional) This question is not relevant to a request for a corporate record/information under the FOI Act.
□ Yes
□ No